Clinical Trials Directory

Trials / Completed

CompletedNCT03615365

COPD Breathing Record Study 2

Characterisation of COPD Breathing Records During Exacerbations

Status
Completed
Phase
Study type
Observational
Enrollment
50 (actual)
Sponsor
TidalSense · Industry
Sex
All
Age
40 Years
Healthy volunteers
Not accepted

Summary

The aim of this study is to collect capnometric (tidal breathing CO2) data using TidalSense's N-Tidal C Data Collector Device. The data collected will be examined for correlation with currently accepted assessment techniques for COPD (spirometry, vital signs and pulse oximetry) and the patient's clinical condition (stable, worsening, improving). The patient numbers and study duration have been determined by power calculations to provide a statistically significant sample size, based on expected number of exacerbations (mild, moderate and severe) from the patient cohort. The data will also be examined to assess the predictive possibility of a non-invasive self-care personal CO2 monitoring device to identify COPD exacerbations.

Detailed description

Study Design: This is an uncontrolled, non-randomised, un-blinded longitudinal observational data collection study with the N-Tidal C Data Collector Device in patients with COPD. Patients will be identified from the Cambridge COPD Centre. This unit sees patients following emergency admissions, GP referrals and has a regional referral base for complex COPD. Patients' medical records will be reviewed and classified according to GOLD criteria. Those patients who are classified as COPD with appropriate inclusion criteria (below) will be invited to participate. Patients who give informed consent will be screened for the study. The N-Tidal C Data Collector Device will be explained to the patients and they will be trained how to use it. All patients will complete a short daily diary record. Patients will undergo a clinical assessment of COPD during screening at Addenbrooke's Hospital. All patients will be assessed five times: at the start, 2 weeks, 10 weeks, 18 weeks and at the end of the 26 week study period. A brief follow-up telephone review will be conducted approximately 2 weeks after the end of the monitoring period. At each assessment, capnometry measurements will be taken in addition to vital signs and pulse oximetry. The study will not interfere with routine management of the patient's condition.

Conditions

Timeline

Start date
2017-08-15
Primary completion
2018-10-18
Completion
2018-11-23
First posted
2018-08-03
Last updated
2023-06-02

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT03615365. Inclusion in this directory is not an endorsement.